Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 4/20 | 1.00 |
| ▸ | YAP1 | P46937 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TNNI3K | Q59H18 | 7/20 | 0.49 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALDH3A1 | P30838 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | OXTR | P30559 | 1/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20779435 | 1.00 | TEAD1 (1.00) | TEAD1YAP1TSHRL3MBTL1TNNI3K | |
| SCHEMBL20767258 | 0.92 | TEAD1 (0.85) | TEAD1YAP1TSHRL3MBTL1TNNI3K | |
| SCHEMBL24788977 | 0.90 | TEAD1 (0.82) | TEAD1YAP1TSHRL3MBTL1TNNI3K | |
| SCHEMBL20766513 | 0.89 | TEAD1 (0.80) | TEAD1YAP1TSHRL3MBTL1TNNI3K | |
| SCHEMBL22718256 | 0.89 | TEAD1 (0.80) | TEAD1YAP1TSHRL3MBTL1TNNI3K | |
| SCHEMBL29438870 | 0.89 | TEAD1 (0.80) | TEAD1YAP1TSHRL3MBTL1TNNI3K | |
| SCHEMBL25790336 | 0.87 | TEAD1 (0.77) | TEAD1YAP1TNNI3KALDH3A1 | |
| SCHEMBL20767405 | 0.87 | TEAD1 (0.77) | TEAD1YAP1TSHRL3MBTL1TNNI3K | |
| SCHEMBL22718190 | 0.87 | TEAD1 (0.77) | TEAD1YAP1TSHRL3MBTL1TNNI3K | |
| SCHEMBL20767350 | 0.87 | TEAD1 (0.77) | TEAD1YAP1TSHRL3MBTL1TNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025054190-A1 | PHARMACEUTICAL FORMULATIONS AND DOSING SCHEDULES OF A YAP/TAZ-TEAD INHIBITOR | VIVACE THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | claimed |
| WO-2025122956-A1 | COMBINATION THERAPY | VIVACE THERAPEUTICS, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| CN-119954725-A | TEAD inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2025054190-A1 | PHARMACEUTICAL FORMULATIONS AND DOSING SCHEDULES OF A YAP/TAZ-TEAD INHIBITOR | VIVACE THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| CN-114466839-B | TEAD inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20240148733-A1 | COMBINATION THERAPY | GENENTECH INC (US) | 2024-05-09 | — | — | US | disclosed |
| EP-4340883-A1 | COMBINATION THERAPY | GENENTECH, INC. (US) | 2024-03-27 | — | — | EP | disclosed |
| CN-117337193-A | combination therapy | 基因泰克公司 | 2024-01-02 | — | — | CN | disclosed |
| WO-2023154811-A2 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) DEGRADERS AND USES THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-08-17 | — | — | WO | disclosed |
| CN-111542315-B | Benzosulfonyl compounds | 维瓦斯治疗公司 | 2023-05-12 | — | — | CN | disclosed |
| WO-2022246459-A9 | COMBINATION THERAPY | GENENTECH, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022246459-A1 | COMBINATION THERAPY | GENENTECH, INC. (US) | 2022-11-24 | — | — | WO | disclosed |
| EP-3691623-B1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS INC (US) | 2022-10-05 | — | — | EP | disclosed |
| EP-3976194-A2 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148733-A1 | COMBINATION THERAPY | KRAS, YAP1, HRAS | TEAD1 10/4885YAP1 2/4885TSHR 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.